Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists

Menopause

Volumn 14, Issue 1, 2007, Pages 20-28

  Power, Michael L ^a   Schulkin, Jay ^a   Rossouw, Jacques E ^b  

^a AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Hormone therapy; Menopause; Survey; Women's Health Initiative

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMENTIA; FEMALE; HORMONAL THERAPY; HUMAN; MALE; MEDICAL SPECIALIST; OSTEOPOROSIS; PHYSICIAN ATTITUDE; PRESCRIPTION; QUESTIONNAIRE; RANDOMIZATION; RESIDENCY EDUCATION; SEX DIFFERENCE; VAGINAL DRYNESS; VASOMOTOR DISORDER; WOMEN'S HEALTH;

ATTITUDE OF HEALTH PERSONNEL; DATA COLLECTION; DRUG UTILIZATION; FEMALE; GYNECOLOGY; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MENOPAUSE; OBSTETRICS; PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; WOMEN'S HEALTH;

EID: 33846075757     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000229571.44505.cb     Document Type: Article

References (15)

1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
2. Cushing KL, Weiss NS, Voigt LF, McKnight B, Beresford SA. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 1998;91:35-39.
3. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253.
6. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
7. Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 2005;84:1589-1601.
8. Power ML, Zinberg S, Schulkin J. A survey of obstetrician-gynecologists concerning practice patterns and attitudes toward hormone therapy. Menopause 2006;13:434-441.
9. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002;137:834-839.
10. ACOG Task Force on Hormone Therapy. Hormone therapy. Obstet Gynecol 2004;104 (Suppl 4):S1-S129.
11. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
12. Bestul MB, McCollum M, Hansen LB, Saseen JJ. Impact of the Women's Health Initiative trial results on hormone replacement therapy. Pharmacotherapy 2004;24:495-499.
13. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983-1988.
14. Geller SE, Studee L, Chandra G. Knowledge, attitudes, and behaviors of healthcare providers for botanical and dietary supplement use for postmenopausal health. Menopause 2005;12:49-55.
15. Power ML, Schulkin J. Obstetrician-gynecologists' patients' knowledge of and attitudes toward hormone therapy: a survey. J Reprod Med 2006;51:525-532.